IRIS
SCHETTINI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 431
EU - Europa 172
AS - Asia 63
AF - Africa 10
Continente sconosciuto - Info sul continente non disponibili 1
Totale 677
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 425
IT - Italia 98
CN - Cina 33
NL - Olanda 28
IN - India 18
DE - Germania 12
CI - Costa d'Avorio 9
IE - Irlanda 9
VN - Vietnam 6
CA - Canada 5
GB - Regno Unito 5
DK - Danimarca 4
FR - Francia 4
FI - Finlandia 3
UA - Ucraina 3
ES - Italia 2
SG - Singapore 2
AM - Armenia 1
BE - Belgio 1
BZ - Belize 1
EU - Europa 1
ID - Indonesia 1
IL - Israele 1
IR - Iran 1
MA - Marocco 1
MK - Macedonia 1
RS - Serbia 1
RU - Federazione Russa 1
Totale 677
Salva come PNG Salva come JPEG
Città #
Chandler 132
Ashburn 33
Amsterdam 28
Millbury 23
Napoli 20
Pune 16
Beijing 15
Des Moines 11
Lawrence 11
Nanjing 8
Princeton 8
Naples 7
Wilmington 7
Bologna 6
Dong Ket 6
Ottawa 5
Milan 4
Battipaglia 3
Boston 3
Pellezzano 3
Seattle 3
Tianjin 3
Castelnuovo del Garda 2
Fairfield 2
Jacksonville 2
Kronberg 2
Pomigliano d'Arco 2
Redwood City 2
San Jose 2
Shenyang 2
Spinetta Marengo 2
Teano 2
Toftlund 2
Vercelli 2
Aci Sant'Antonio 1
Angri 1
Ardabil 1
Belgrade 1
Belize City 1
Boardman 1
Caivano 1
Caserta 1
Casoria 1
Catania 1
Changsha 1
Dublin 1
Duncan 1
Ercolano 1
Guangzhou 1
Hebei 1
Jakarta 1
Jiaxing 1
Kortrijk 1
Krefeld 1
Kunming 1
London 1
Luco dei Marsi 1
Modugno 1
Montemesola 1
New York 1
Paris 1
Pavullo Nel Frignano 1
Rabat 1
Rome 1
Salerno 1
San Francisco 1
Scordia 1
Tel Aviv 1
Torre Del Greco 1
Valencia 1
Vetralla 1
Yerevan 1
Totale 417
Salva come PNG Salva come JPEG
Nome #
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. 60
The Impact of Translational Research in Breast Cancer Care: Can We Improve the Therapeutic Scenario? 46
Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues 43
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis 41
Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: A retrospective study 39
Combined effect of obesity and diabetes on early breast cancer outcome: A prospective observational study 36
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis 36
Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives 35
Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going 29
Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series 29
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study 29
Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study 28
Effect of rescue fractional microablative CO2 laser on symptoms and sexual dysfunction in women affected by vulvar lichen sclerosus resistant to long-term use of topic corticosteroid: a prospective longitudinal study 28
PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom? 27
Post-Progression Treatments after Palbociclib plus Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer Patients: What Is the Better Choice? 25
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study 23
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer 21
Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis 21
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer 20
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis 20
Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in breast cancer 19
Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis 17
Endocrine‐based treatments in clinically‐relevant subgroups of hormone receptor‐positive/her2‐negative metastatic breast cancer: Systematic review and meta‐analysis 17
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study 11
Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests 11
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 10
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer 1
Totale 722
Salva come PNG Salva come JPEG
Categoria #
all - tutte 3.179
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.179
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20195 0 0 0 0 0 0 0 0 0 5 0 0
2019/202058 16 1 4 1 3 4 0 7 0 5 12 5
2020/202168 1 0 6 15 11 4 4 4 9 1 6 7
2021/2022134 0 0 3 0 0 2 0 4 13 13 56 43
2022/2023270 22 31 13 13 38 36 2 23 37 35 16 4
2023/2024129 8 32 9 9 9 37 1 17 5 2 0 0
Totale 722